New RNA-Protein Interactions Identified as Potential Coronavirus Drug Targets
Researchers at the University of California, Riverside and the University of California, San Diego have mapped previously unknown RNA-protein interactions across the SARS-CoV-2 genome, identifying structural targets that could lead to new coronavirus antiviral drugs less vulnerable to rapid viral evolution.
- Mapping RNA-protein interactions across the SARS-CoV-2 genome revealed specific binding sites involving the RNA-dependent RNA polymerase and nucleocapsid proteins.
- Disrupting these conserved interaction sites using antisense oligonucleotides significantly reduced viral replication in both animal cell cultures and human lung cells.
- Because these core viral processes are conserved among coronaviruses, targeting them offers an early proof of concept for broad-spectrum antiviral treatments independent of individual viral variants.
Mapping Undescribed Viral Binding Sites
The study, published in Nature Communications, utilized a technique known as enhanced cross-linking and immunoprecipitation (eCLIP) to survey the viral genome. Led by Joy Xiang at UC Riverside and Gene Yeo at UC San Diego, the research team examined where viral proteins interact with RNA across the entire genome rather than restricting analysis to regions predicted in advance to be important. News-Medical reported that the team identified viral RNA binding sites for three specific proteins: the primase cofactor NSP8, the RNA-dependent RNA polymerase NSP12, and the nucleocapsid protein N.
The rapid evolution of SARS-CoV-2 continues to present challenges for antiviral drug development as mutations reduce the effectiveness of treatments designed to recognize variable features like the spike protein. By focusing on essential machinery that the virus cannot easily change, researchers aim to prevent drug resistance. Remdesivir currently targets the RNA-dependent RNA polymerase enzyme that copies the viral RNA genome, while Paxlovid targets proteins involved in processing long protein chains.
Regulatory Roles of Viral RNA and Protein N
Among the findings, investigators identified an interaction between the nucleocapsid protein and a region at the beginning of the viral genome known as the 5′ untranslated region. Newswise reported that this region contains a complex RNA structure highly conserved among coronaviruses. The researchers observed that its interaction with the protein appears to regulate translation, the process by which viral RNA produces proteins.
The study also uncovered a previously unknown interaction between the RNA-dependent RNA polymerase and the RNA encoding viral protein NSP3. According to UA.News, this suggests that viral RNA may perform active regulatory functions rather than merely serving as a passive template for protein synthesis. Viruses look simpler than humans at first glance, but there’s a lot of underlying complexity to their molecular biology we’re only just beginning to unravel,
Yeo stated.
Targeting Conserved Interactions With Antisense Oligonucleotides
To test whether these newly identified interaction sites could be disrupted therapeutically, the research team designed antisense oligonucleotides and locked nucleic acids. These short, modified nucleic acid sequences bind complementary sections of RNA to block their interactions with other molecules. According to findings highlighted by Newswise, blocking these interaction sites significantly reduced viral replication in animal cells and human lung cells alike.
The research builds on broader scientific priorities outlined in a 2024 review published in Nature Reviews Microbiology regarding broad-spectrum antivirals for future outbreak preparedness. Funding for the study was provided in part by Emergency COVID-19 Research Seed Funding from the University of California Office of the President.
Animal Studies Will Determine Viability of Therapeutic Approaches
Investigators emphasize that the work remains at an early stage. All experiments to date have been performed in cell cultures, and animal studies are required to determine whether these findings translate into viable therapeutic approaches for human infection. Xiang noted that understanding these core biological interactions will allow drug developers to build treatments that remain effective across diverse coronaviruses regardless of emerging variants.
We need to understand the fundamental biology of these viruses instead of just being reactive to outbreaks,
Xiang said.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.